Highlights HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Real-time Estimate Cboe BZX Other stock markets 12:27:57 2024-07-03 pm EDT			5-day change	1st Jan Change
0.587 ^USD	+0.93%		-8.38%	-27.60%

Jul. 01	HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	MT
Jul. 01	HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	Jul. 01	CI
HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting	Jun. 04	CI
HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting	May. 23	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab	Apr. 25	CI
HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	Apr. 24	CI
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	Apr. 10	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus	Nov. 20	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023	Nov. 03	CI
Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023	23-10-22	CI
HOOKIPA Pharma Inc. Announces Publication of Preclinical Data of Hepatitis B Virus Therapeutic Vaccine Developed in Collaboration with Gilead Sciences	23-10-18	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
HOOKIPA Pharma Inc. Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with Hpv16+ Head and Neck Cancers	23-05-31	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Highlights

Filters